Response to Comments: Transthoracic Echocardiography (TTE)

This policy notes that CAMZYOS (mavacamten) is indicated for symptomatic obstructive hypertrophic cardiomyopathy in patients who are NYHA Class II–III. Use of CAMZYOS is permitted only as part of the CAMZYOS REMS program and requires documentation of REMS enrollment plus clinical confirmation of diagnosis and NYHA class.

"CAMZYOS (mavacamten) is indicated for treatment of symptomatic obstructive hypertrophic cardiomyopathy in patients who are NYHA Class II–III."

Sign up to see full coverage criteria, indications, and limitations.